Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study

By afschroeder • June 21, 2025

Maertens JA, Thompson GR 3rd, Spec A, Donovan FM, Hammond SP, Bruns AHW, Rahav G, Shoham S, Johnson R, Rijnders B, Schaenman J, Hoenigl M, Morrissey CO, Mehta SR, Heath CH, Koehler P, Paterson DL, Slavin MA, Fortún J, Nguyen MH, Patterson TF, Uspenskaya O, Van de Veerdonk FL, Verweij PE, Aoun M, Georgala A, Alexander BD, Chayakulkeeree M, Mehra V, Miceli MH, Sikka MK, Solé A, Walsh TJ, Aguado JM, Holland SM, Moussa M, Rautemaa-Richardson R, Bazaz R, Schwartz S, Walsh SR, Plate M, Yehudai-Ofir D, Brüggemann RJ, Cornely OA, Ostrosky-Zeichner L, Vazquez JA, White PL, Cornelissen K, Ross GG, Fitton L, Dane A, Zinzi D, Rex JH, Chen SC. Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study. Lancet Infect Dis. 2025 Jun 17:S1473-3099(25)00224-5. doi: 10.1016/S1473-3099(25)00224-5. Epub ahead of print. PMID: 40541222.

Tags: Infectious Diseases, Kern, Publications

Uptake of the COVID-19 vaccine and its association with vaccine information and misinformation in Malawi

Songo J, Whitehead HS, Phiri K, Kalande P, Lungu E, Phiri S, van Oosterhout J, Moses A, Hoffman RM, Moucheraud C. Uptake of the COVID-19[...]

Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment

Munroe ES, Grandits GA, Hyzy RC, Prescott HC, Barrett TW, Dewar RL, Engen N, Goodman AL, Hatlen TJ, Highbarger H, Holland TL, Hughes G, Jensen[...]

Three Cases of Vertical Transmission of Clade Ib Mpox Virus

Vakaniaki EH, Kuispond NS, Hirata Y, Bangwen E, Brosius I, Kinganda-Lusamaki E, Ozono S, Katano H, Ndunge LG, Mulopo-Mukanya N, Tshomba JC, De Vos E,[...]